Targeting tumor-selective membrane-associated PCNA enables selective antibody–drug conjugate therapy
Findings establish mPCNA as a functionally validated, tumor-selective internalizing target and support RC14-MMAE as a first-in-class mPCNA-directed ADC with broad translational potential.